產(chǎn)品名稱：Prothrombin Screen ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號(hào)：DE7230 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說(shuō)明： Special remarks: Anti-Prothrombin Screen is an indirect solid phase enzyme immunoassay (ELISA) for the simultaneous quantitative measurement of IgG, IgM and IgA class autoantibodies against Prothrombin in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders. Anti-phospholipid (aPL) antibodies have been associated with venous and arterial thrombosis as well as with recurrent fetal loss. Patients with these symptoms and high aPL antibody levels have been diagnosed as having the anti-phospholipid antibody syndrome (APS). Anti-phospholipid syndrome can occur in patients with systemic lupus erythematosus (SLE) or other autoimmune diseases (secondary anti-phospholipid syndrome) or in patients without underlying autoimmune disease (primary anti-phospholipid syndrome). In clinical practice anti-cardiolipin antibodies detected by ELISA is one of the most established and standardised tests for diagnosis of the antiphospholipid syndrome. However, the family of aPL antibodies has recently expanded to include a heterogeneous group of antibodies whose specificity is directed against phospholipid binding proteins or their complex with phospholipids. Among the phospholipid binding proteins, the best studied is ß2-glycoprotein 1 (ß2?GP1). Another phospholipid binding protein, Prothrombin (factor II), exerts a procoagulant activity via a prothrombinase complex, triggering fibrinogen conversion to fibrin. Autoantibodies can inhibit the formation of the thrombokinase complex. This complex is formed by the binding of prothrombin to phospholipids on the damaged cell membrane where prothrombin, then, is enzymatically transformed into thrombin. Thrombin, itself, causes blood coagulation. Antibodies directed against coagulation factors, like prothrombin, are pathogenic antibodies, that circulate in the blood stream. They directly inhibit the coagulation factors, and hence prolong the coagulation time. These autoantibodies are also found in association with autoimmune diseases. The presence of antibodies to prothrombin is associated with thrombosis in patients with SLE and APS. And it was found that high autoantibody levels against prothrombin imply a risk of deep venous thrombosis and pulmonary embolism and could be involved in the development of the thrombotic processes. Furthermore, it was demonstrated that elevated levels of antibodies to prothrombin predict a risk of myocardial infarction. 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國(guó)內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個(gè)國(guó)家近五十萬(wàn)種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長(zhǎng)和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對(duì)生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號(hào)
